Article
Oncology
Kuo Li, Xiaonian Cao, Bo Ai, Han Xiao, Quanfu Huang, Zheng Zhang, Qian Chu, Li Zhang, Xiaofang Dai, Yongde Liao
Summary: Salvage surgery after tumor downstaging shows promise as a therapeutic strategy for improving progression-free survival in patients with advanced NSCLC. It may provide a new therapeutic option for multidisciplinary comprehensive treatment of lung cancer.
Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Allison L. Rosenstein, Alexandra L. Potter, Priyanka Senthil, Vignesh Raman, Arvind Kumar, Ashok Muniappan, Mark F. Berry, Chi-Fu Jeffrey Yang
Summary: This study evaluated the outcomes of delayed resection after radiation therapy for non-small cell lung cancer. The results showed acceptable perioperative outcomes among a highly selected patient cohort.
ANNALS OF THORACIC SURGERY
(2023)
Review
Oncology
Akira Hamada, Junichi Soh, Tetsuya Mitsudomi
Summary: Salvage surgery can be considered as an effective treatment option for patients with locally advanced lung cancer, especially for those with late local recurrence or significant metabolic response. In certain conditions, the accumulation of real-world evidence may be necessary for further evaluation, as phase III trials are often difficult to conduct.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Yanxia Xiao, Pu Liu, Jie Wei, Xin Zhang, Jun Guo, Yajun Lin
Summary: The high morbidity and mortality of non-small cell lung cancer pose significant health threats. However, with the identification of carcinogenic drivers and the use of targeted drugs, the prognosis for patients has greatly improved. Nonetheless, the unknown carcinogenic drivers and the issue of drug resistance in targeting therapy still hinder effective treatment. This review discusses the mechanisms of targeted-drug resistance and newly identified targets, highlighting the importance of research in driving individualized treatment for non-small cell lung cancer.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, Rami Manochakian, Yujie Zhao, Yanyan Lou
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with non-small-cell lung cancer (NSCLC) being the most common type. Although targeted therapy has improved survival in NSCLC patients with actionable mutations, therapy resistance and lack of targeted agents for certain oncogenic driver mutations remain challenges. This review summarizes emerging targeted therapies that have been tested in first-in-human clinical trials in the past year.
Article
Oncology
Yoichi Ohtaki, Kimihiro Shimizu, Hiroyuki Suzuki, Kenji Suzuki, Masahiro Tsuboi, Tetsuya Mitsudomi, Motoshi Takao, Tomohiro Murakawa, Hiroyuki Ito, Kenichi Yoshimura, Morihito Okada, Masayuki Chida
Summary: Salvage surgery after TKI treatment for non-small cell lung cancer patients is safe and feasible, potentially prolonging overall survival time by reducing the local tumor burden.
Review
Biochemistry & Molecular Biology
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
Summary: Lung cancer is the most deadly cancer worldwide, with non-small cell lung cancer (NSCLC) being the main type and EGFR as a key driver gene. Despite the effectiveness of EGFR-tyrosine kinase inhibitors in targeted therapy, acquired resistance remains a significant challenge, prompting the exploration of combination treatment options.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Cardiac & Cardiovascular Systems
Kimihiro Shimizu, Yoichi Ohtaki, Kenji Suzuki, Hiroshi Date, Motohiro Yamashita, Toshihiko Iizasa, Hiroyuki Ito, Kenichi Yoshimura, Morihito Okada, Masayuki Chida
Summary: The study found that pathological nodal stage was an independent prognosticator in the chemoradiotherapy or conventional external beam group, while age 70 years and greater was the only independent prognosticator in the stereotactic body radiotherapy or ion beam radiotherapy group. Overall, patients undergoing salvage surgery can have reasonable outcomes.
ANNALS OF THORACIC SURGERY
(2021)
Review
Biochemistry & Molecular Biology
Jiajia Wu, Zhenghong Lin
Summary: Precision medicine has expanded treatment options for NSCLC patients through targeted therapy based on genetic and epigenetic cues. Antibodies and inhibitors that target critical gene-mediated signaling pathways have improved patient prognosis. However, resistance due to genetic alterations poses significant challenges in the treatment of metastatic NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Natalia Motas, Veronica Manolache, Marco Scarci, Victor Nimigean, Vanda Roxana Nimigean, Laurentiu Simion, Madalina Cristiana Mizea, Oana Gabriela Trifanescu, Bianca Galateanu, Mirela Gherghe, Cristina Mirela Capsa, Diego Gonzalez-Rivas, Mihnea Dan Davidescu
Summary: Salvage surgery for small-cell lung cancer (SCLC) is a relatively new and rare concept, but it can be considered as an alternative treatment in selected patients with limited disease. It has similar postoperative morbidity to salvage surgery for non-small cell lung cancer (NSCLC), with no postoperative mortality, and a median estimated overall survival of 92% at 2 years and 66% at 5 years. Salvage lung resection for SCLC offers good local control and a favorable survival outcome.
Review
Oncology
Mahmood Araghi, Reza Mannani, Ali Heidarnejad Maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi, Reza Akhavan-Sigari
Summary: Lung cancer is the leading cause of cancer-related death globally, and significant advancements have been made in the last decade in diagnosing and treating NSCLC through molecular translational research. Targeted therapy, specifically aimed at specific genes, proteins, or the tumor microenvironment, has shown the most successful outcomes in NSCLC treatment. Efforts are currently focused on improving targeted therapy to enhance cancer treatment outcomes and patient quality of life. This updated study provides a comprehensive discussion on tumor target antigens and targeted therapy-related agents, along with a summary of available clinical trial studies for NSCLC patients.
CANCER CELL INTERNATIONAL
(2023)
Review
Oncology
Zixiong Shen, Binxu Qiu, Lin Li, Bo Yang, Guanghu Li
Summary: This review provides an overview of the characteristics and fusion methods of RET genes, analyzes the advantages and disadvantages of different detection methods for RET fusions, summarizes the recent application of non-selective and selective RET fusion-positive inhibitors, and discusses the mechanisms and coping strategies of resistance to these inhibitors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Bor-Shiuan Shyr, Chien-Sheng Huang, Hui-Shan Chen, Po-Kuei Hsu, Chao-Hua Chiu, Han-Shui Hsu, Chun-Ming Tsai, Yuh-Min Chen
Summary: This study aimed to investigate the impact of primary lung resection and systemic treatment on disease progression and survival in patients with oligometastatic NSCLC. The results showed no significant differences in perioperative complications, hospital length of stay, disease progression, overall death, median PFS, and OS between patients who received primary lung resection and systemic treatment. It was also found that patients with single-organ metastasis had significantly longer PFS and OS than those with oligometastases. Nonsolitary metastasis was identified as the only independent predictor of PFS.
ANNALS OF THORACIC SURGERY
(2022)
Article
Cardiac & Cardiovascular Systems
Marnix J. A. Rasing, Max Peters, Amy C. Moreno, Erik F. N. Hofman, Gerarda J. M. Herder, Pim W. N. Welvaart, Franz M. N. H. Schramel, Joyce E. Lodeweges, Steven H. Lin, Joost J. C. Verhoeff, Peter S. N. van Rossum
Summary: In this study, a prediction model was developed to estimate the chance of incomplete resection in non-small cell lung cancer patients based on preoperative factors. Independent predictors were identified through internal and external validation, and an internationally validated nomogram was presented.
ANNALS OF THORACIC SURGERY
(2021)
Article
Endocrinology & Metabolism
Zhiqiang Ma, Dong Liu, Shouyin Di, Zhipei Zhang, Weimiao Li, Jiao Zhang, Liqun Xu, Kai Guo, Yifang Zhu, Xiaofei Li, Jing Han, Xiaolong Yan
JOURNAL OF PINEAL RESEARCH
(2019)
Article
Pathology
Shouyin Di, Mingyang Li, Zhiqiang Ma, Kai Guo, Xiaofei Li, Xiaolong Yan
PATHOLOGY RESEARCH AND PRACTICE
(2019)
Review
Pharmacology & Pharmacy
Zhiqiang Ma, Xiaoyan Zhang, Liqun Xu, Dong Liu, Shouyin Di, Weimiao Li, Jiao Zhang, Hongmei Zhang, Xiaofei Li, Jing Han, Xiaolong Yan
PHARMACOLOGICAL RESEARCH
(2019)
Review
Cell Biology
Zhiqiang Ma, Liqun Xu, Dong Liu, Xiaoyan Zhang, Shouyin Di, Weimiao Li, Jiao Zhang, Russel J. Reiter, Jing Han, Xiaofei Li, Xiaolong Yan
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2020)
Article
Endocrinology & Metabolism
Shouyin Di, Zheng Wang, Wei Hu, Xiaolong Yan, Zhiqiang Ma, Xiaofei Li, Weimiao Li, Jianyuan Gao
FRONTIERS IN ENDOCRINOLOGY
(2020)
Article
Cardiac & Cardiovascular Systems
Wei-an Song, Bo-shi Fan, Shou-yin Di, Jun-qiang Liu, Jia-hua Zhao, Si-yu Chen, Cai-ying Yue, Shao-hua Zhou, Tai-qian Gong
Summary: This study compared the efficacy of three-field lymphadenectomy (3-FL) with standard two-field lymphadenectomy (2-FL) in minimally invasive esophagectomy (MIE) for esophageal cancer. The results showed that 3-FL allowed for more lymph nodes harvest and accurate staging without increased surgical risks, despite longer operation time compared to 2-FL.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Bo-Shi Fan, Xing-Tong Wang, Shou-Yin Di, Jia-Hua Zhao, Si-Yu Chen, Shao-Hua Zhou, Cai-Ying Yue, Wei-An Song, Tai-Qian Gong
Summary: The study revealed that neoadjuvant sintilimab combined with chemotherapy in stage III non-small cell lung cancer patients showed promising efficacy with a high rate of major pathological responses and acceptable treatment-related adverse events.
TRANSLATIONAL CANCER RESEARCH
(2022)
Editorial Material
Oncology
Boshi Fan, Taiqian Gong
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Boshi Fan, Zengfeng Sun, Jing Lu, JunQiang Liu, Jiahua Zhao, Shaohua Zhou, Shouyin Di, Weian Song, Taiqian Gong
Summary: This study compared the 3-year survival and recurrence outcomes between three-field lymphadenectomy (3-FL) and two-field lymphadenectomy (2-FL) in minimally invasive esophagectomy (MIE) for esophageal cancer. The results showed similar survival and disease-free survival rates between the two groups, but the 3-FL group had a higher incidence of cervical lymphatic recurrence compared to the 2-FL group.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Shuohua Wang, Shouyin Di, Jing Lu, Shun Xie, Zhenyang Yu, Yingkui Liang, Taiqian Gong
Summary: This study investigated the predictive value of F-18-FDG PET/CT for pathological response after neoadjuvant immunochemotherapy (NICT) in patients with esophageal squamous cell carcinoma (ESCC). The study found that the scan parameters of PET/CT before and after treatment were significantly associated with the pathological response and could help predict the patient's response.
Article
Biochemistry & Molecular Biology
Shouyin Di, Chongxi Fan, Zhiqiang Ma, Mingyang Li, Kai Guo, Donghui Han, Xiaofei Li, Deguang Mu, Xiaolong Yan
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2019)
Article
Oncology
Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana
Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.
Article
Oncology
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda
Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.
Review
Oncology
Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu
Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.
Article
Oncology
Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima
Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.